NCT03046797: Obese-FOB

Boussignac Valve and Fibroptic Intubation in Morbidly Obese Patients, Can it be a Solution?

Completed NA Last updated 8 January 2018

What this trial tests

NA trial testing Fibroptic intubation through Boussignac valve opening in Morbid Obesity in 50 participants. Completed in 30 December 2017.

Timeline

5 February 2017

Primary endpoint
30 December 2017

30 December 2017

Quick facts

Lead sponsor	Mansoura University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	50
Start date	5 February 2017
Primary completion	30 December 2017
Estimated completion	30 December 2017
Sites	2 locations across Egypt

Drugs / interventions tested

• Fibroptic intubation through Boussignac valve opening
• Classic Fibroptic intubation

Conditions studied

• Morbid Obesity — all drugs for Morbid Obesity →

Sponsor

Mansoura University

Who can join

Adults 20 to 45, any sex, with Morbid Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, fiberoptic intubation through Boussignac valve, while ventilation of morbidly obese patients is maintained through the ventilator, will be studied. Researchers suggest that the technique will allow more time for intubation trial rather than conventional techniques of intubation without ventilation. the Primary outcome will be the decrease of desaturation events during intubation. Secondary variables will include; stress response to intubation, the incidence of hypercapnia, hemodynamic response to intubation, successful intubation, the time required to intubation and operator satisfaction.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.